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Abstract 
Background: Artificial intelligence (AI) has the potential to transform our healthcare systems significantly. New AI 
technologies based on machine learning approaches should play a key role in clinical decision‑making in the future. 
However, their implementation in health care settings remains limited, mostly due to a lack of robust validation pro‑
cedures. There is a need to develop reliable assessment frameworks for the clinical validation of AI. We present here an 
approach for assessing AI for predicting treatment response in triple‑negative breast cancer (TNBC), using real‑world 
data and molecular ‑omics data from clinical data warehouses and biobanks.
Methods: The European “ITFoC (Information Technology for the Future Of Cancer)” consortium designed a frame‑
work for the clinical validation of AI technologies for predicting treatment response in oncology.
Results: This framework is based on seven key steps specifying: (1) the intended use of AI, (2) the target population, 
(3) the timing of AI evaluation, (4) the datasets used for evaluation, (5) the procedures used for ensuring data safety 
(including data quality, privacy and security), (6) the metrics used for measuring performance, and (7) the procedures 
used to ensure that the AI is explainable. This framework forms the basis of a validation platform that we are building 
for the “ITFoC Challenge”. This community‑wide competition will make it possible to assess and compare AI algorithms 
for predicting the response to TNBC treatments with external real‑world datasets.
Conclusions: The predictive performance and safety of AI technologies must be assessed in a robust, unbiased and 
transparent manner before their implementation in healthcare settings. We believe that the consideration of the 
ITFoC consortium will contribute to the safe transfer and implementation of AI in clinical settings, in the context of 
precision oncology and personalized care.
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Background
Artificial intelligence (AI) has the potential to transform 
our healthcare systems considerably and will play a key 
role in clinical decision-making in the future [1]. AI has 
been in the spotlight since the 1980’s, when the first 
“expert systems” simulating the clinical reasoning for 
clinical decisions emerged [2]. With the huge increase in 
medical data over the last few decades, new approaches 
have been developed (principally machine learning (ML), 
including neural networks). ML techniques trained on 
clinical datasets [2] have already proved useful for diag-
nostic applications [3–5] and risk prediction [6].
Despite the enthusiasm surrounding AI, their use in 
healthcare settings remains limited. AI technologies 
require rigorous assessment before they can be used 
in clinical practice [7]. For example, the first AI-based 
device to receive market authorization from the FDA 
was assessed with a large prospective comparative clini-
cal trial including 900 patients from multiple sites [4]. 
AI technologies must satisfy stringent regulations for 
approval as medical devices, because (1) the decision 
support provided is optimized and personalized con-
tinuously in real time, according to the phenotype of the 
patient [7]; (2) the performance of AI depends strongly 
on the training datasets used [8], resulting in a large risk 
of AI performing less well in real practice [9–11] or on 
another group of patients or institutions [9]. It is, there-
fore, essential to assess the performance and safety of AI 
before its introduction into routine clinical use.
Robust evaluations are required for AI to be trans-
ferred to clinical settings, but, in practice, only a few 
such systems have been validated with external datasets 
[12, 13]. A recent literature review reported that most 
studies assessing AI did not include the recommended 
design features for the robust validation of AI [9]. There 
is, therefore, a need to develop frameworks for the robust 
validation of the performance and safety of AI with reli-
able external datasets [14, 15].
Finding, accessing and re-using reliable datasets is a 
real challenge in medicine (contrasting with other FAIR 
data collections [16]). However, with the development 
of clinical data warehouses within hospitals, it should 
become easier to obtain access to “real datasets”. The 
benefit of using real-world data for research purposes 
[17], and, particularly, for generating complementary evi-
dence during AI life cycles, has been highlighted by the 
European Medicines Agency [18]. Real-world data from 
clinical data warehouses may, therefore, constitute a 
valuable source of reliable external datasets for validating 
AI before its implementation in healthcare settings.
Guidelines on the regulation of AI technologies include 
high-level directions, but not specific guidance on the 
practical steps in AI evaluation [19]. Here, we propose 
a framework for assessing the clinical performance and 
safety of AI in the context of precision oncology. More 
precisely, the objective is to use real-world data collected 
from clinical data warehouses and biobanks to assess AI 
technologies for predicting the response to anti-cancer 
drugs. We developed this framework as part of the Euro-
pean Flag-Era project ‘ITFoC (Information Technology 
for the Future of Cancer)’ [20], to validate AI algorithms 
with -omics and clinical data for the prediction of treat-
ment response in triple-negative breast cancer (TNBC). 
This framework could help AI developers and institutions 
to design clinically trustworthy decision support systems, 
and to assess them with a robust methodology.
Methods
Breast cancer is the most common cancer in women 
worldwide [21, 22]. The most aggressive type is triple-
negative breast cancer (TNBC), characterized by a lack 
of estrogen receptor, progesterone receptor and human 
epidermal growth factor expression, together with a high 
histologic grade and a high rate of mitosis [23]. TNBC 
accounts for 10–20% of all breast cancers, and has a very 
poor prognosis, with chemotherapy the main therapeutic 
option [23, 24]. New targeted and personalized therapies 
are, therefore, urgently required [23].
In recent decades, cancer treatments has followed a 
“one-size-fits-all” approach based on a limited set of 
clinical criteria. Recent advances, rendering sequenc-
ing techniques more widely available, are providing new 
opportunities for precision oncology, the personaliza-
tion of treatment based on a combination of clinical and 
molecular data, and improvements in drug efficacy, with 
fewer side effects.
In this context, many AI models have been developed, 
based on the detailed molecular characterization of indi-
vidual tumors and patients. They model the effects and 
adverse effects of drugs in the context of TNBC treat-
ment [25, 26]. However, these AI models often lack clini-
cal validation, and require further external evaluation. 
The ITFoC (Information Technology for the Future of 
Cancer) consortium [20], a multidisciplinary group from 
six European countries, has proposed a new approach 
to the unbiased validation of these AI models. This 
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approach involves evaluating the performance and safety 
of these AI models through robust clinical evaluation 
with reliable and external real-world datasets, before 
their implementation in healthcare settings. The ITFoC 
consortium has designed a framework to meet this goal. 
This framework is based on seven key steps specifying 
(Fig. 1): (1) the intended use of AI, (2) the target popula-
tion, (3) the timing of AI evaluation, (4) the datasets used 
for evaluation, (5) the procedures used for ensuring data 
safety (including data quality, privacy and security), (6) 
the metrics used for measuring performance, and (7) the 
procedures used to ensure that the AI is explainable.
Results
The framework designed by the “ITFoC consortium” 
follows seven principles that we consider essential for 
the assessment of AI technologies. This framework was 
developed to support a community-based programming 
contest to be held during “Pink October”. This “ITFoC 
challenge”, will open a platform enabling various teams 
(academic, research, and MedTech organizations) to test 
their AI-based approaches with TNBC datasets provided 
by our partners for the purpose of this competition.
We describe here the framework and the paral-
lel actions planned for the setting up of the “ITFoC 
challenge”.
Step 1: Specify the intended use of AI
The first step in AI assessment is accurately defining its 
intended use (for medical purposes) [7], together with 
its input (i.e. the data required to run the AI), and out-
put (i.e. the results provided by AI) parameters.
Once the intended use of AI is clearly stated, it is 
important to be sure that:
• AI is used only to address questions that are relevant 
and meaningful for the medical community. Indeed, 
AI may be irrelevant if it is used in a correct, but not 
useful manner in healthcare settings [27]. It is, there-
fore, important to define clearly the benefits of AI for 
a particular clinical scenario.
• AI complies with ethical, legal and social standards 
[27, 28]. As stated by the High-Level Expert Group 
on AI established by the European Commission [29], 
AI should (1) comply with all applicable laws and 
regulations, (2) adhere to ethical principles and val-
ues, (3) not disadvantage people from particular soci-
odemographic backgrounds or suffering from certain 
conditions, (4) not increase discrimination based on 
ethnicity or sex.
Fig. 1 The seven key steps needed for the clinical validation of AI technologies
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Planned actions
In the “ITFoC challenge”, we aim to assess AI with the fol-
lowing intended use: predicting the response of TNBC 
patients to treatment, regardless of their origin or ethnic 
background. More precisely, AI should be able to predict, 
at the time of diagnosis, whether particular patients are 
likely to respond to standard treatment, so that prob-
able non-responders can be offered alternative treatment 
options.
The expected clinical impact is an improvement in 
survival rates for TNBC patients, particularly those not 
responding to standard treatment.
Step 2: Clearly specify the target population
The second step in AI assessment is accurately defining 
the target population. AI must be evaluated on inde-
pendent datasets similar to the target population of the 
AI technology. The population is defined during the 
development phase, by specifying patient and disease 
characteristics, in a similar manner to the definition 
of eligibility criteria in conventional clinical trials. The 
sets of patients selected for the assessment should be 
representative of the target population, and consecu-
tive inclusion or random selection should be used for 
patient recruitment, at multiple sites, to limit the risk 
of spectrum bias (i.e. the risk of the patients selected 
not reflecting the target population) [15], and to ensure 
that the results can be generalized.
Contrary to the AI validation and training stages, 
which require large datasets, AI evaluation does not 
necessarily require ‘big data’ [15]. As in randomized 
clinical trials, the study sample should be determined 
according to the study hypothesis, expected effect (e.g. 
superiority, non-inferiority) and degree of importance 
(differences important or unimportant) [15].
Planned actions
In the “ITFoC challenge”, the target population is “women 
who have been diagnosed with TNBC”. We need to assess 
AI performance in terms of treatment response. We 
must therefore select patients who have already received 
first-line treatment (making it possible to compare the 
predicted and observed responses in a retrospective mul-
ticentre cohort of TNBC patients).
Step 3: Specify the timing of AI evaluation
The third step in AI assessment is clearly defining the 
timing of the evaluation. As in drug development, vari-
ous phases can be distinguished for AI evaluation (Fig. 2):
• The “fine-tuning” phase is an essential part of AI 
development. It is equivalent to the “preclinical 
phase” in drug development, when drugs are tested 
in a laboratory setting. Here, AI is evaluated inter-
nally in three steps: training, internal validation, and 
testing. The training step involves training the algo-
rithm on a subset of so-called “training” data. The 
internal validation involves fine-tuning the algorithm 
or selecting the most optimized parameters. The test 
step corresponds to the final internal assessment of 
the performance of the algorithm.
• The “clinical validation” phase follows the internal 
validation and testing of AI. It is equivalent to phases 
I and II of clinical trials, in which drug efficacy and 
safety are assessed in a limited number of patients. 
Here, the performance and safety of AI are assessed 
with external data. The goal is to check that AI will 
not result in lost opportunities for patients through 
the generation of false-positive or false-negative pre-
dictions (i.e. for patients predicted to respond to a 
treatment who do not in reality, and vice-versa).
• Finally, patient outcomes are assessed after clini-
cal validation with external datasets. This phase is 
equivalent to the phase III of clinical trials, in which 
new drugs are compared to standard treatment in 
randomized controlled trials (RCT). Here, AI is 
implemented in healthcare settings, and its effect on 
patient outcomes and the efficiency of the healthcare 
system is assessed with real patients, via a RCT.
Planned actions
In the “ITFoC challenge”, we will focus on the “clini-
cal validation” phase. Akin to early-phase drug trials, 
the goal will be to determine whether the AI developed 
is sufficiently accurate and safe for transfer into clinical 
practice for further assessment in RCTs.
Step 4: Specify the datasets used for AI evaluation
The fourth step in AI assessment is the selection of reli-
able and representative datasets:
• Publicly accessible datasets [1] are available through 
public repositories (e.g. ArrayExpress [30], GEO [31]) 
or are released by research and/or medical institu-
tions (e.g. TCGA, or ICGC collections). However, 
most are more suitable for bioinformatics than for 
clinical informatics [1].
• Patient databases store retrospective or prospective 
datasets generated by clinical trials or routine care 
(real-world data).
• ‘Clinical trial’ datasets are collected in the con-
trolled environment of a specific clinical trial 
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Fig. 2 Evaluation of AI‑timing
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(Table  1), from a restricted population that may 
not be representative of the general population. 
The data collection process is time-consuming 
and costly, but the resulting data should be homo-
geneous, highly reliable and should have a well-
structured format. However, such datasets are not 
generally made publicly available, for the follow-
ing reasons [32]: the potential loss of competitive 
advantage for the organization funding the study; 
the possibility of invalidating the results published 
through secondary analyses; the costs associated 
with data sharing and, finally, due to ethical and 
scientific considerations. Moreover, data collec-
tion is usually limited to predefined sets of vari-
ables, and it may, therefore, be difficult to re-use 
secondarily these data to address questions not 
included in the initial protocol [32].
• Real-world datasets are usually stored in clinical 
data warehouses (Table 1). These datasets are col-
lected throughout patient care and have various 
clinical sources (structured and unstructured clin-
ical records, laboratory, pharmacy, and radiology 
results, etc.) [17, 33]. The collection of these data 
is less time-consuming and costly than that for 
clinical trial datasets. However, their exploitation 
requires careful data quality management, because 
they are highly variable and were initially collected 
for clinical purposes rather than for research [34–
37].
Split-sample validation involves randomly splitting 
datasets into separate parts, which are then used for 
both the development and internal evaluation of AI [12, 
15]. This method is relevant only during the develop-
ment phase, and cannot be used to validate the gen-
eralizability of AI. Indeed, there is a risk of overfitting 
bias (i.e. the AI fits too exactly to the training data), and 
spectrum bias (i.e. the internal dataset is not represent-
ative of the population on which the AI will be used). 
Validation on completely independent external data-
sets is required to overcome these limitations and for 
validation of the generalizability of AI [15]. Geographic 
sampling (i.e. using datasets collected by independent 
investigators from different sites) could considerably 
limit both biases, and improve the estimation of AI 
generalizability in healthcare settings [15].
Planned actions
In the “ITFoC challenge”, we are working with retrospec-
tive real-world datasets collected from the clinical data 
warehouses and biobanks of multiple hospitals, ensuring 
that the TNBC population is broadly represented.
The inclusion criteria for datasets are:
• A follow-up period of at least three years, to ensure 
the standardized evaluation of treatment response
• High-quality data extracted from a clinical data ware-
house or from a dedicated cancer database
• Biological samples must be available in biobanks for 
additional -omics analyses, if required.
• Patients must have signed a consent form for the 
reuse of their data and the reuse of their samples for 
research purposes
The objective is not to acquire thousands of patient 
datasets of variable quality, but to collect a representative 
set of high-quality patient data.
Step 5: Specify the procedures used to ensure data safety
The fifth step in AI assessment is ensuring data safety, 
including data quality, privacy and security, during the 
evaluation phase.
Table 1 Clinical trial versus Real‑world datasets for AI evaluation
Clinical trial datasets Real-world datasets
Setting Experimental Real world
Population Representativeness Selective sample Large sample
Type Homogeneous Heterogeneous
Size +/− ++++
Time period for recruitment and follow‑
up
Limited Long
Data Type Clinical +/− ‑omics Clinical +/− ‑omics
Collected by Dedicated specialist professionals Various healthcare professionals
Quality +++ +/−
Need for data management +/− +++
Need for anonymization + +
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Data quality
Standardization is strongly recommended, to guarantee 
the quality, sharing, portability and reusability of data 
for AI evaluation [38]. Standardization is defined as the 
representation of heterogeneous data with consensual 
specifications [38]. It includes specifications for both data 
fields (i.e. variables) and their value sets (i.e. codes) [38]. 
Standardization is highly dependent on the type of data-
sets involved.
Clinical data Clinical data are highly complex, for sev-
eral reasons: (1) they come from different sources (e.g. 
electronic health records, reimbursement claims data), 
(2) they have various formats (e.g. free text, numbers, 
images), and representations (e.g. structured, semi-struc-
tured, unstructured); (3) the level of granularity is highly 
variable, ranging from general to fine-grained concepts; 
(4) datasets are not complete (e.g. missing data); (5) data-
set content varies within and between institutions.
Various common data models can be used to standard-
ize clinical datasets. These models include the CDISC 
(Clinical Data Interchange Standards Consortium) model 
for “clinical trial datasets”, which can be used to ensure 
information system interoperability between healthcare 
and clinical research, and the OMOP (Observational 
Medical Outcomes Partnership) common data model for 
real-world datasets. The data values must also be harmo-
nized by the use of terminologies ensuring interoperabil-
ity between AI systems, such as the ICD 10 (International 
Classification of Diseases) for the standardization of 
medical diagnoses, LOINC (Logical Observation Iden-
tifiers Names and Codes) for biological tests, Med-
DRA (Medical Dictionary for Regulatory Activities) for 
adverse events, and so on. Most standard terminologies 
are integrated into the UMLS (Unified Medical Language 
System) metathesaurus, which can be used as a global 
thesaurus in the biomedical domain.
-Omics data -Omics data are complex: (1) they are 
generated by different techniques, with different bioin-
formatic tools; (2) they may be based on different types 
of NGS (next-generation sequencing) data, such as 
WGS (whole-genome sequencing), WES (whole-exome 
sequencing), and RNA-sequencing, or on data from prot-
eomics and metabolomics platforms; (3) their integration 
and interpretation remain challenging, due to their size 
and complexity, and the possibility of experimental and 
technical errors during sample preparation, sequencing 
and data analysis [39].
-Omics data can be standardized at any stage from data 
generation to data interpretation. For example, MIAME 
(minimum information about a microarray experi-
ment) [40] and MAGE (microarray gene expression data 
modeling and exchange standards) have been developed 
for microarray experiments [41]. The most widely used 
format for variant identification is VCF (variant clinical 
format), which includes a number of fields for genomic 
coordinates, reference nucleotide, and variant nucleotide, 
for example, but also metadata adding meaningful infor-
mation relating to variants: e.g. gene symbol, location, 
type, HGVS (human genome variation society) nomen-
clature, predicted protein sequence alterations and 
additional resources, such as cross-references to cancer-
specific and general genomic databases and prior in silico 
algorithm-based predictions.
Standardization of clinical and -omics data Standardi-
zation makes it possible to combine data from multiple 
institutions. It also ensures the consistency of datasets, 
and improves the quality and reliability of clinical and 
-omics data. These aspects are crucial, to maximize the 
chances of predicting the real impact of AI on the health-
care process. Indeed, the ultimate performance of AI 
depends strongly on the quality of data used for evalua-
tion [12, 13].
Planned actions In the “ITFoC” challenge, we will apply 
a range of internationally accepted standards for breast 
cancer data, to overcome issues of data heterogeneity 
and variability associated with the use of data of different 
provenances [34, 35] and to ensure access to high-quality 
real-world datasets [38]
Clinical datasets will be standardized with the OMOP 
common data model [42] for data structure and the OSI-
RIS model [43] for data content. The OMOP CDM is sup-
ported by the OHDSI consortium (Observational Health 
Data Sciences and Informatics), and OSIRIS is supported 
by the French National Institute of Cancer. Both stand-
ards include a list of concepts and source values, con-
sidered the minimal dataset necessary for the sharing of 
clinical and biological data in oncology. Items and values 
are structured and standardized according to interna-
tional medical terminologies, such as ICD 10, LOINC, 
SNOMED CT. A standardized TNBC data model based 
on these models will be used: items will be added, 
removed and/or transformed, and values will be adapted 
to TNBC data (e.g. the values of the “biomarker” item are 
limited to RO, RP and HER2 receptors, Ki67). The instan-
tiated model contains the dataset specifications provided 
to participants in this challenge. The database will be 
populated locally through dedicated extract-transform-
load pipelines.
It may not be possible to extract -omics data directly 
from clinical data warehouses, because these data are 
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not widely collected in routine care. If not already pre-
sent in the electronic health record of the patient, -omics 
data will be generated from patient samples stored in 
biobanks. For the challenge, WES data, RNA-sequencing 
data, microRNA expression levels and metabolomic data 
will be obtained from primary tumor samples, and from 
blood samples as a control. Data quality will be ensured 
by using only freshly frozen tumors with a celll content of 
more than 30% (as determined by a pathologist). Multi-
level -omics data contain a wealth of potentially relevant 
information, including molecular variants (directly or 
indirectly) affecting clinically significant pathways. Their 
incorporation into the challenge dataset should greatly 
increase the predictive power of the AI technologies 
evaluated.
Data privacy
The patients’ right to privacy must be respected. Patients 
must be informed about the storage and use of their 
data, and must have signed a consent form authorizing 
the collection and use of their data for research [44, 45]. 
Within Europe, data privacy is regulated by the General 
Data Protection Regulation (GDPR) [45]), which protects 
patients against the inappropriate use of their data. Such 
regulations ensure that (1) patients can choose whether 
or not to consent to the collection of their data, (2) 
patients are informed about the storage and use of their 
data (principle of transparency), (3) data are stored in 
an appropriate manner (principle of integrity), (4) data 
are used only for certain well-defined purposes, and (5) 
patients have the right to change their minds and to with-
draw consent at any time.
Planned actions In the “ITFoC challenge”, data privacy 
will be respected:
• Only datasets from patients who have signed a con-
sent form authorizing the reuse of their data and 
samples for research will be included in the chal-
lenge.
• The clinical data will be pseudo-anonymized by 
state-of-the-art methods (and in accordance with the 
GDPR), without altering the scientific content. Any 
clinical information that could be used, directly or 
indirectly, to identify the individual will be removed 
(e.g. dates will be transformed into durations (com-
puted as a number of days)).
Data security
AI evaluation should be hosted and managed on a secure 
platform [46], that can ensure that confidentiality, integ-
rity and/or the availability of patient information are not 
compromised deliberately or accidentally [44]. Any plat-
form used for AI evaluation should implement the strict-
est control over access, to ensure that data are available 
only to authorized parties [44], only for the duration of 
the evaluation [44], and that any personal data (including 
both data directly linked to a patient, such as surname, 
and indirectly linked to the patient, such as diagnosis 
date) are removed [47].
Planned actions In the “ITFoC challenge”, data security 
will be ensured by using a dedicated ITFoC data space. 
Workflows will be created between local clinical data 
warehouses and the local ITFoC data space, for standardi-
zation of the datasets with respect to the standard TNBC 
model. Each standardized dataset will be transferred to a 
secure platform, on which it will be stored (Fig. 3).
Participants will assess their AI technologies with the 
same datasets hosted on a secure platform, but they will 
not be allowed to access datasets directly. Clinical and 
-omics data will be inaccessible throughout the duration 
of the challenge, and participants will be provided only 
with the specifications of the datasets.
Step 6: Specify the metrics used for measuring AI 
performance
The sixth step in AI assessment is defining the metrics 
used to evaluate the performance of the AI algorithm.
The intrinsic performance of the AI itself is assessed 
during the “fine-tuning” and the “clinical validation” 
phases. Discrimination performance is measured in 
terms of sensitivity and specificity for binary outputs [15]. 
By plotting the effects of different levels of sensitivity and 
specificity for different thresholds, a ROC (receiver oper-
ating characteristics) curve can be generated [48]. This 
ROC curve represents the discrimination performance of 
a particular predictive algorithm [15]. The most common 
metric used is the AUC (area under the ROC Curve), the 
values of which lie between 0 and 1. Algorithms with high 
levels of performance have a high sensitivity and specific-
ity, resulting in an AUC close to 1 [15, 48].
Calibration performance is measured for quantitative 
outputs, such as probabilities [15]. It is used to determine 
whether predicted probabilities agree with the real prob-
abilities [15]. The predicted probabilities are plotted on 
the x-axis, and the observed real probabilities are plotted 
on the y-axis, to generate a calibration plot [15]. This plot 
can be used to estimate the goodness of fit between the 
predicted and real probabilities [49]. Bland–Altman plots 
can also be used to analyze the agreement between the 
predicted and the observed probabilities [50].
A more detailed discussion of the statistical methods 
used to measure AI performance is beyond the scope of 
this article but can be found elsewhere [49].
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Fig. 3 Data workflow for the ITFoC challenge
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The clinical performance of AI in real clinical settings is 
assessed during the “patient outcome assessment” phase. 
AI metrics, such as AUC, are not always understood by 
clinicians [51], and do not necessarily reflect clinical effi-
cacy [52]. There is a need to determine the effect of AI 
on patient outcomes in real-life conditions. Ideally, the 
effects of AI should be compared to a gold standard [53] 
or baseline (i.e. standard procedure) in an RCT using 
standard statistical approaches [15].
Planned actions
In the “ITFoC challenge”, we will assess the performance 
of AI itself with the binary criterion “predicted response 
to treatment” during the clinical validation phase. For 
each AI algorithm, various metrics will be reported, 
including AUC, confusion matrix, sensitivity, specificity, 
positive and negative predictive values.
The evaluation will be carried out by a scientific com-
mittee, independent of the ITFoC organizational com-
mittee. This scientific committee will include members 
from various disciplines (e.g. bioinformaticians, medical 
doctors, data scientists, statistical and machine-learning 
experts) and from various international institutions (aca-
demic, research and hospital institutions).
Step 7: Specify the procedures to ensure AI explainability
The seventh step in the assessment of AI is examining the 
underlying algorithm [54, 55]. This step has two expected 
benefits. First, it may prevent an inappropriate represen-
tation of the dataset used for training/validation. Sec-
ond, it may reveal the learning of unanticipated artifacts 
instead of relevant inputs [54].
The input data must be analyzed first [54]. The type 
(structured or unstructured), format (e.g. text, numbers, 
images), and specifications (e.g. variables used) of the 
data must be assessed. A better comprehension of the 
input data should ensure that the data used by the AI are 
comprehensive and relevant to clinical practice.
The underlying algorithm should also be analyzed [54]. 
The code, documented scripts, and the computer envi-
ronment should be evaluated by independent research-
ers. Ideally, independent researchers should even run the 
pipeline, check the underlying AI methods and evaluate 
the explainability of the outputs [54]. However, AI devel-
opers may be reluctant to share their codes openly, for 
scientific or economic reasons. In such cases, alternatives 
can be found, such as a trusted neutral third party signing 
a confidentiality form, or a virtual computing machine 
running the code with new datasets [54], or the provision 
of documentations about the AI.
Planned actions
In the “ITFoC challenge”, we aim at explain why some AI 
successfully predict treatment response, whereas oth-
ers fail. Each AI developer participating in the challenge 
should provide the data specifications used by the AI. 
We will encourage the AI developers to share their codes 
openly. Alternatively, they could opt for restricted code 
sharing with the scientific committee (the scientific com-
mittee will sign a confidentiality agreement).
Discussion
We describe here the framework designed by the ITFoC 
consortium for the assessment of AI technologies for 
predicting treatment response in oncology. This frame-
work will be used to construct a validation platform for 
the “ITFoC Challenge”, a community-wide competition 
for assessing and comparing AI algorithms predicting 
the response to treatments in TNBC patients from real-
world datasets.
Use of real-world datasets for validating AI technologies
The systematic and rigorous validation of AI technologies 
is essential before their integration into clinical practice. 
Such evaluation is the only way to prevent unintentional 
harm, such as misdiagnosis, inappropriate treatment or 
adverse effects, potentially decreasing patient survival. 
To date, only a few AI-based solutions have actually been 
clinically validated [9], mostly exclusively on internal 
datasets, with no external validation. RCTs in which AI 
technologies are compared to the gold standard (i.e. rou-
tine care delivered by medical experts) are the strongest 
and most reliable approach for assessing AI performance 
and safety [56]. Such trials provide a more detailed evalu-
ation, including a range of relevant parameters, such as 
patient benefits in terms of quality of life, acceptance by 
physicians, integration into the clinical workflow, and 
economic impact. However, RCTs are costly, both finan-
cially and in terms of time required, and should be pre-
ceded by early-phase studies [4].
Here, we support the idea that when AI technologies 
reach a state of sufficient “maturity”, they should undergo 
clinical validation with external real-world datasets. This 
would make it possible to measure the performance 
and safety of AI quickly and reliably in conditions close 
to those encountered in real-life. This validation pro-
cess would save both money and time, due to the use of 
real-world datasets from clinical data warehouses. At the 
end of this early validation step, if the performance of a 
specific AI technology falls short of expectations (e.g. if 
it fails to predict response to treatment, or is considered 
unsafe), then it can be rejected (as in early-phase trials 
for drugs), and no further evaluation in RCTs is required. 
If an AI is validated clinically with these real-world 
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datasets, it can be considered a good candidate and 
allowed to progress to the next stage in evaluation (i.e. an 
RCT). The validation process outlined here (“validation 
step with retrospective real-world datasets”) should thus 
be an integral part of the entire AI evaluation process, 
constituting the decisive step concerning whether or not 
to perform a RCT.
Use of a community-wide competition to assess AI 
technologies
We propose here to organize the “validation step” in the 
form of a community-wide competition. Competition-
based approaches are increasingly being seen as relevant 
in the medical informatics domain, with participating 
teams usually tackling a challenge over a limited time 
period, with access to an anonymized dataset for the test-
ing of methods. For example, the i2b2 (Informatics for 
Integrating Biology and the Bedside) project includes 
a “Natural Language Processing” challenge for assess-
ing methods for understanding clinical narratives [57]. 
Competition-based approaches have also been developed 
in oncology (e.g. the Sage Bionetworks—DREAM Breast 
Cancer Prognosis Challenge, designed for developing 
computational models that can predict breast cancer 
survival [58, 59]; and the Prostate DREAM Challenge, 
for identifying prognostic models capable of predicting 
survival in patients with metastatic castration-resistant 
prostate cancer [46]). The utility of these crowdsourced 
challenges for the community has clearly been demon-
strated. They have multiple advantages: (1) they allow the 
development of models that outperform those developed 
with traditional research approaches [58, 60], (2) they 
encourage collaboration between teams for the improve-
ment of models [60], and (3) they provide more trans-
parent results, because both favorable and unfavorable 
results are published [58, 60].
We derived a framework from these competition-
based approaches. Our approach is based on the same 
principles as these existing challenges, but focusing on 
the combination of real-world data collected from clini-
cal data warehouses (rather than data collected through 
RCTs), and -omics data generated by next-generation 
sequencing techniques. The results of the “ITFoC chal-
lenge” will provide essential proof-of-principle evidence 
for the use of real-world datasets for validating AI tech-
nologies in a competition setting, as an essential precur-
sor to RCTs.
Accelerating AI transfer to healthcare settings
We propose a framework for the clinical validation of AI 
technologies before their transfer to clinical settings and 
clear actions in the domain of TNBC treatment. Both the 
framework and the planned actions can be generalized 
to other questions in oncology, with minor adaptations. 
For instance, for diagnosis, other datasets could be con-
sidered (e.g. images, signals). Likewise, we propose here 
the use of real world dataset from various healthcare 
centres, to guarantee the volume and representativeness 
of the dataset. Similarly, when dealing with rare can-
cers, the datasets may come from various centers, and 
may even be extended to other sources, such as clinical 
research data. Dataset from other sources have already 
been successfully used for the assessment of AI in breast 
and prostate cancers [46, 58]. Furthermore, the metrics 
used to assess AI performance may also differ, depend-
ing on the type of cancer and the intended use of AI (e.g. 
for diagnosis, the primary outcome could be compared to 
the diagnosis made by an oncologist).
We believe that a platform, as described here, could 
help to accelerate AI transfer to healthcare settings in 
oncology. AI systems are currently considered to be 
medical devices that can only be implemented in health 
centers after the demonstration of their safety and effi-
cacy through a large prospective RCT [4]. However, this 
is time-consuming and expensive, and there is a risk of 
patient outcome studies becoming obsolete by the time 
the results become available [15]. The use of a valida-
tion platform has several advantages: (1) several AI tech-
nologies can be assessed in parallel for the same price 
(whereas a RCT is usually designed to assess a single 
AI technology); (2) the platform can be re-used for fur-
ther AI evaluations; (3) new datasets can easily be added 
to the platform; (4) transparency is guaranteed, as the 
results are communicated even if unfavorable. For all 
these reasons, validation platforms constitute a credible 
route towards establishing a rigorous, unbiased, trans-
parent and durable approach to the assessment of AI 
technologies.
Supporting precision medicine
Clinical care decision are traditionally driven by patient 
symptoms and disease characteristics. In precision 
oncology, the scope is extended to the patient pheno-
type, preclinical symptoms, tumor characteristics and 
the complex molecular mechanisms underlying disease 
[61]. Recent advances in genetics and sequencing tech-
nologies are now enabling clinicians to include molec-
ular aspects of the disease in their clinical decision 
processes, and advances in metabolomics have facili-
tated considerations of the functional activity of can-
cer cells [62, 63]. The use of -omics data in routine care 
(e.g. genomic, metabolomic or proteomic data [64]), is 
strongly supported by the European Medicines Agency 
[18], and could lead to significant improvements in 
patient care.
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Here, we provide support for the idea that -omics anal-
ysis should be part of the clinical decision process. The 
“ITFoC Challenge” aims to demonstrate the benefits of 
integrating clinical data warehouses and biobanks into 
the clinical care process, in accordance with the findings 
of previous studies [65, 66]. By combining clinical and 
-omics data, AI tools may facilitate the delivery of treat-
ments that are personalized according to the characteris-
tics of the patients and their tumors, thereby increasing 
of the chances of survival and decreasing side effects. By 
designing the “ITFoC Challenge”, we aim to encourage 
the development of AI based on clinical and -omics data 
for the prediction of treatment response in cancer, and 
the personalization of cancer treatment.
Conclusions
We hereby propose a framework for assessing AI tech-
nologies based on real-world data, before their use in 
healthcare settings. This framework includes seven 
key steps specifying: (1) the intended use of AI, (2) 
the target population, (3) the timing for AI evaluation, 
(4) the datasets selected for evaluation, (5) the proce-
dures used to ensure data safety, (6) the metrics used to 
measure performance, and (7) the procedures used to 
ensure that the AI is explainable. The proposed frame-
work has the potential to accelerate the transfer of AI 
into clinical settings, and to boost the development of 
AI solutions using clinical and -omics data to predict 
treatment responses and to personalize treatment in 
oncology. Here, we applied this framework to the estab-
lishment of a community-wide competition in the con-
text of predicting treatment responses in TNBC.
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